Developer and provider of RNA interference ( RNAi ) technology designed to treat liver diseases. Ribo Life Science is based in Suzhou, China and was founded in 2007. It is now publicly traded; this page covers its private-market history, where its last recorded valuation was $1.2 billion (Jan 2026). It has raised $285 million.
Last price · $/share
—
Implied valuation
$1.2B
Total raised
$285.3M
Last round
—
Team — not yet on record
No current team members for Ribo Life Science are on record yet. People surface from round filings, company disclosures, and coverage sessions.
Pro members can request priority coverage with a 48-hour turnaround.
Free account
More of Ribo Life Science with a free account
·The complete investor list: 12 names
·Watch Ribo Life Science: the Monday email on marks, rounds and moves
